{"id":"azt-3tc-nvp-azt-d4t-nvp-truvada-nvp","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Rash (nevirapine-related)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"variable","effect":"Lipodystrophy (AZT/D4T-related)"},{"rate":"5-10","effect":"Peripheral neuropathy"},{"rate":"5-10","effect":"Anemia (AZT-related)"}]},"_chembl":{"chemblId":"CHEMBL4567342","moleculeType":"Unknown","molecularWeight":"431.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combinations pair nucleoside reverse transcriptase inhibitors (AZT, 3TC, D4T) or integrase inhibitors (Truvada contains tenofovir/emtricitabine) with the non-nucleoside reverse transcriptase inhibitor (NVP/nevirapine) to block multiple steps of HIV replication. By targeting reverse transcriptase through different mechanisms, these regimens reduce the likelihood of resistance development and achieve sustained viral suppression.","oneSentence":"These are combination antiretroviral regimens that inhibit HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:26.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment and prevention"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00669487","phase":"PHASE3","title":"A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2008-04","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT01694017","phase":"PHASE4","title":"Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy","status":"COMPLETED","sponsor":"Tufts University","startDate":"2012-11","conditions":"HIV","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP","genericName":"AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP","companyName":"SEARCH Research Foundation","companyId":"search-research-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These are combination antiretroviral regimens that inhibit HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}